ALGS
Aligos Therapeutics Inc
NASDAQ: ALGS · HEALTHCARE · BIOTECHNOLOGY
$5.99
+0.34% today
Updated 2026-04-30
Market cap
$36.94M
P/E ratio
—
P/S ratio
16.90x
EPS (TTM)
$-2.45
Dividend yield
—
52W range
$4 – $14
Volume
0.2M
Aligos Therapeutics Inc (ALGS) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | $107.73M | $146.52M | $265.30M | $235.37M | $146.69M | $151.53M | $70.09M |
| Cash & equivalents | $24.04M | $69.56M | $220.38M | $186.82M | $81.35M | $135.70M | $37.00M |
| Current assets | $92.37M | $120.23M | $250.02M | $204.42M | $133.54M | $141.08M | $62.14M |
| Total liabilities | $121.48M | $211.41M | $45.26M | $50.64M | $42.79M | $59.45M | $99.07M |
| Current liabilities | $7.49M | $13.82M | $30.27M | $38.96M | $33.13M | $23.91M | $21.74M |
| Long-term debt | — | — | — | — | — | — | — |
| Shareholder equity | $-13.75M | $-64.89M | $220.04M | $184.73M | $103.90M | $92.08M | $-28.97M |
| Retained earnings | $-13.93M | $-66.20M | $-174.74M | $-303.07M | $-399.12M | $-486.80M | $-618.01M |
| Accounts receivable | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — |